Vtesse Overview
- Year Founded
-
2014
- Status
-
Acquired/Merged
- Employees
-
10
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$200M
Vtesse General Information
Description
Developer of new drug treatments designed to treat severe and life-threatening diseases. The company's new drug treatments, includes treatment for rare disease Niemann-Pick Disease Type C (NPC), enabling patients with NPC and other lysosomal storage diseases to get treated. It also offers information, resources and support that can be used to better understand NPC and to cope with its impact on lives.
Contact Information
Website
www.vtessepharma.comCorporate Office
- 910 Clopper Road
- Suite 220 South
- Gaithersburg, MD 20878
- United States
Corporate Office
- 910 Clopper Road
- Suite 220 South
- Gaithersburg, MD 20878
- United States
Vtesse Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Merger/Acquisition | 03-Apr-2017 | $200M | Completed | Startup | ||
| 2. Early Stage VC (Series A) | 25-Jul-2016 | Completed | Clinical Trials - Phase 2 | |||
| 1. Accelerator/Incubator | Completed | Clinical Trials - Phase 2 |
Vtesse Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
Vtesse Comparisons
Industry
Financing
Details
Vtesse Competitors (38)
One of Vtesse’s 38 competitors is Ralexar Therapeutics, a Venture Capital-Backed company based in Wayne, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Ralexar Therapeutics | Venture Capital-Backed | Wayne, PA | ||||
| Voyager Therapeutics | Formerly VC-backed | Lexington, MA | ||||
| Neurona Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| NeuroNascent | Venture Capital-Backed | Clarksville, MD | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA |
Vtesse Patents
Vtesse Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2016276774-A1 | Hydroxypropyl beta-cyclodextrin compositions and methods | Inactive | 10-Jun-2015 | ||
| CA-2988529-A1 | Hydroxypropyl beta-cyclodextrin compositions and methods | Inactive | 10-Jun-2015 | ||
| EP-3307278-A1 | Hydroxypropyl beta-cyclodextrin compositions and methods | Inactive | 10-Jun-2015 | ||
| EP-3307278-A4 | Hydroxypropyl beta-cyclodextrin compositions and methods | Inactive | 10-Jun-2015 | ||
| US-20160361345-A1 | Hydroxypropyl beta-cyclodextrin compositions and methods | Inactive | 10-Jun-2015 | A61K31/724 |
Vtesse Signals
Vtesse Former Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alexandria Venture Investments | Venture Capital | Minority | ||
| Bay City Capital | Venture Capital | Minority | ||
| Cydan | Accelerator/Incubator | Minority | ||
| Lundbeckfonden BioCapital | Venture Capital | Minority | ||
| New Enterprise Associates | Venture Capital | Minority |
Vtesse FAQs
-
When was Vtesse founded?
Vtesse was founded in 2014.
-
Where is Vtesse headquartered?
Vtesse is headquartered in Gaithersburg, MD.
-
What is the size of Vtesse?
Vtesse has 10 total employees.
-
What industry is Vtesse in?
Vtesse’s primary industry is Drug Discovery.
-
Is Vtesse a private or public company?
Vtesse is a Private company.
-
What is the current valuation of Vtesse?
The current valuation of Vtesse is .
-
What is Vtesse’s current revenue?
The current revenue for Vtesse is .
-
How much funding has Vtesse raised over time?
Vtesse has raised $42M.
-
Who are Vtesse’s investors?
Alexandria Venture Investments, Bay City Capital, Cydan, Lundbeckfonden BioCapital, and New Enterprise Associates are 5 of 6 investors who have invested in Vtesse.
-
Who are Vtesse’s competitors?
Ralexar Therapeutics, Voyager Therapeutics, Neurona Therapeutics, NeuroNascent, and Inovio Pharmaceuticals are some of the 38 competitors of Vtesse.
-
When was Vtesse acquired?
Vtesse was acquired on 03-Apr-2017.
-
Who acquired Vtesse?
Vtesse was acquired by Sucampo Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process